Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


Home > Press > pSivida Strengthens Board with the Appointment of an Australian based Non-executive Director

pSivida Limited (NASDAQ:PSDV) (ASX:PSD) (Xetra:PSI) today announced the appointment of Dr. Katherine Woodthorpe based in Sydney, Australia as a Non-executive Director of the Company.

pSivida Strengthens Board with the Appointment of an Australian based Non-executive Director

BOSTON, MA and PERTH, Australia | Posted on August 3rd, 2007

Dr. Woodthorpe is currently the Chief Executive of AVCAL, the Australian Private Equity and Venture Capital Association. Dr. Woodthorpe has an extensive background as a management adviser and director, including working with Australian technology companies seeking venture funding to being a board member of listed companies. She has consulted with government groups on innovation and commercialization.

With more than 25 years in the technology and commercialization industry, Dr. Woodthorpe has held a broad range of management and board positions. In addition to her role as Chief Executive of the AVCAL, Dr. Woodthorpe is Chair of the Antarctic Climate and Ecosystems Cooperative Research Centre, Director of Insearch Ltd and Council Member, University of Technology Sydney.

"We are very fortunate to have Katherine join the Board," said pSivida's Managing Director, Dr. Paul Ashton. "Katherine brings a unique and powerful blend of scientific and business skills that we believe will greatly assist pSivida."

Prior to AVCAL, Dr. Woodthorpe worked as a professional Non-Executive Director and management adviser. Her areas of expertise included developing strategies for rapid growth and commercialization of technology products and services.

Mr. Stephen Lake who joined the Board in July 2004 has decided to stand down as a Director to can focus on the launch of a new technology fund in the UK.

pSivida Non-executive Chairman, Dr. David Mazzo said, "Mr. Lake has provided invaluable assistance in bringing pSivida through and into a new phase of development and the Company thanks Mr. Lake for his significant contribution over the last three years and wishes Mr. Lake well in his new ventures".


About pSivida Limited
pSivida is a global drug delivery company committed to the biomedical sector. Retisert® is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the treatment of AIDS-related CMV Retinitis. Bausch & Lomb owns the trademarks Vitrasert® and Retisert®. pSivida has licensed the technologies underlying both of these products to Bausch & Lomb. The technology underlying Medidur™ for diabetic macular edema is licensed to Alimera Sciences and is in Phase III clinical trials. pSivida has a worldwide collaborative research and license agreement with Pfizer Inc. for other ophthalmic applications of the Medidur™ technology.

pSivida owns the rights to develop and commercialize a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon™, which has applications in drug delivery, wound healing, orthopedics, and tissue engineering. The most advanced BioSilicon™ product, BrachySil™ delivers a therapeutic, P32 directly to solid tumors and is presently in Phase II clinical trials for the treatment of pancreatic cancer.

pSivida’s intellectual property portfolio consists of 71 patent families, 99 granted patents, including patents accepted for issuance, and over 300 patent applications. pSivida conducts its operations from facilities near Boston in the United States, Malvern in the United Kingdom and Perth in Australia.

pSivida is listed on NASDAQ (PSDV), the Australian Stock Exchange (PSD) and on the Frankfurt Stock Exchange on the XETRA system (PSI). pSivida is a founding member of the NASDAQ Health Care Index and the Merrill Lynch Nanotechnology Index.

This release contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we can give no assurance that such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors that are contained in cautionary statements in the Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission, including, without limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to update any oral or written forward-looking statements that may be made by or on behalf of pSivida.

For more information, please click here

pSivida Limited
Brian Leedman
Vice President, Investor Relations
pSivida Limited
Tel: + 61 8 9226 5099

US Public Relations
Beverly Jedynak
Martin E. Janis & Company, Inc
Tel: (312) 943 1103

European Public Relations
Eva Reuter
Accent Marketing Limited
Tel: +49 (254) 393 0740

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Tiny octopods catalyze bright ideas: Rice-led study shows plasmonic sensors and catalysts need not be mutually exclusive November 30th, 2015

Nanoparticles simplify DNA identification and quantification November 27th, 2015

Scientists 'see' detailed make-up of deadly toxin for the first time: Exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia November 25th, 2015

Electric fields remove nanoparticles from blood with ease November 24th, 2015


Tiny octopods catalyze bright ideas: Rice-led study shows plasmonic sensors and catalysts need not be mutually exclusive November 30th, 2015

Graphene microphone outperforms traditional nickel and offers ultrasonic reach November 29th, 2015

Coming to a monitor near you: A defect-free, molecule-thick film November 29th, 2015

Overtaking science fiction with physics: 33-year-old physicist at the University of Kaiserslautern receives 1.5 million euros of EU funding November 29th, 2015

Appointments/Promotions/New hires/Resignations/Deaths

Kerstin Kleese van Dam Named Director of Brookhaven Lab's Computational Science Initiative September 26th, 2015

QD Vision Names Display Industry Veteran Mustafa Ozgen as CEO to Support Aggressive Growth and Market Expansion September 15th, 2015

National Space Society Welcomes Janet Ivey As New NSS Governor: Janet Ivey of Janet's Planet is NOW IN ORBIT as a member of the Board of Governors of the National Space Society August 27th, 2015

National Space Society Welcomes Geoff Notkin As New NSS Governor August 26th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

Car Brands
Buy website traffic